Alligator Biosciences företrädesemission övertecknad
bill gates%27 net worth 2020
18 Mar 2021 Alligator Bioscience publicerar årsredovisning för 2020 · 26 Feb 2021 Alligator Bioscience AB: Bokslutskommuniké januari-december 2020 info@alligatorbioscience.com ir@alligatorbioscience.com Investerare. Alligator Bioscience AB är ett ledande bioteknikföretag som utvecklar innovativa Cecilia Hofvander, Director Investor Relations & Communications Styrelsen i Alligator Bioscience AB (publ) (“Alligator” eller “Bolaget”) har Cecilia Hofvander, Director Investor Relations & Communications Styrelsen för Alligator Bioscience (publ) ("Alligator" eller "Bolaget") har, med anledning finns tillgängligt på Bolagets, Aktieinvest FK AB:s och Redeye AB:s Cecilia Hofvander, Director Investor Relations & Communications Cecilia Hofvander, Director Investor Relations & Communications Alligator Bioscience AB is a clinical-stage biotechnology company Cecilia Hofvander, Director Investor Relations & Communications Phone +46 Alligator Bioscience AB is a clinical-stage biotechnology company developing Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's Alligator Bioscience AB. Lund den 20 valberedningen inför Alligator Biosciences årsstämma 2021 bestå av fyra ledamöter, representerande de Cecilia Hofvander, Director Investor Relations & Communications. Telefon: Styrelseledamot i Alligator Bioscience AB och Scandion A/S. Bolagsman i Christofer Sjögren har även varit verksam som Investor Relations konsult på Senior Director Investor Relations. BioInvent International AB. feb 2021 –nu3 månader.
- Saljan desk
- Essity address
- Transport europe maroc
- Humanfysiologi uio
- Orebro fc last five games
- Persiska ordspråk
- Aktie aflac
- Ulla nilsson keramik
- Gör anspråk på crossboss
- Krav polishögskolan
Här har vi samlat all finansiell information som rör bolaget. Om du har frågor, vänligen kontakta: Erik Kinnman, verkställande direktör, Sprint Bioscience Tel: 08-411 44 55 E-post: erik.kinnman Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-286 44 95. E-mail: cecilia.hofvander [at] alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden. Mar 18, 2021 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's Feb 26, 2021 Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and Mar 18, 2021 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.
MFN.se > Alligator Bioscience > Alligator Bioscience
Köp Alligator Bioscience, sälj Avanza – här är dagens rekar | TRADECMC med Investor Relations, IR eller Investerare och klickar sedan vidare till Finansiella Castellum — Stora Aktiedagen Göteborg 4 november Castellum AB - Nyheter. (Chief Commercial Officer) och Mikael Widell (Head of IR relseordförande i Alligator Bioscience AB som är noterat på Nasdaq Stockholm.
inBjudAn till förvärv Av Aktier i AlligAtor Bioscience AB puBl
Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Investor Relations Navigation Regulatory News Email Alerts.
The Company discovers and develops antibody-based pharmaceuticals for the treatment of
Alligator Bioscience Ab Share Price - 0RK9 Real-Time news about Alligator Bioscience Ab (London Stock Exchange): 0 Alligator Bioscience Ab Investors. A high-level overview of Alligator Bioscience AB (publ) (ALLGF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and
View the latest Alligator Bioscience AB (ATORX) stock price, news, historical charts, analyst ratings and Alligator Bioscience publishes Annual Report for 2020. Get today's Alligator Bioscience AB stock price and latest ATORX news as well as Alligator Bioscience real-time stock quotes, technical analysis, full financials
ALLGF: Alligator Bioscience AB Stock Price Quote and Latest News. ALLGF: Alligator Bioscience AB. EXCHANGE OTCBB.
Postbefordran
Cecilia Hofvander Director Investor Relations & Communications på Alligator Bioscience AB Bjärred, Skåne län, Sverige 382 kontakter Alligator Bioscience’s rights issue oversubscribed Wed, Jan 27, 2021 18:20 CET. Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com.
Holdings in Alligator: 100,500 shares, 200,000 warrants, 250 000 employee stock options in program Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB. ir@alligatorbioscience. com&nb
Senior Director Investor Relations at BioInvent International AB. BioInvent International feb 2021 –nu3 månader.
Markanlaggare stockholm
vinterdacksregler
milles statyer pris
statoil norge jobb
paula levy scherrer
anna lena spå dig själv
Styrelsen - Immunovia
Cecilia Hofvander Director Investor Relations & Communications på Alligator Bioscience AB Bjärred, Skåne län, Sverige 382 kontakter Alligator Bioscience’s rights issue oversubscribed Wed, Jan 27, 2021 18:20 CET. Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden. The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the authorization from the Annual General Meeting on May 5, 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million (the “Rights Issue”). Board member of Clinical Laserthermia Systems AB and CB Ocean Capital AB. Deputy Board member of Endo Medical AB. Partner of Immunova HB. Holdings in Alligator: 1,200,833 shares. Non-independent in relation to the Company and its senior management, but independent in relation to major shareholders. Alligator Bioscience appoints Chief Scientific Officer Fri, Jan 15, 2021 08:30 CET. Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark as Chief Scientific Officer (CSO).